High cost sharing and specialty drug initiation under Medicare Part D : a case study in patients with newly diagnosed chronic myeloid leukemia Research brief (Leonard Davis Institute of Health Economics) Doshi, Jalpa A. author. Li, Bengxiang, author. Huo, Hairong, author. Pettit, Amy R., author. Kumar, Rishab, author. Weiss, Brendan M., author. Huntington, Scott F., author. Cost Sharing Drug Costs Medicare Part D -- economics KEY FINDINGS: Medicare Part D beneficiaries with higher out-of-pocket costs are more likely to delay starting or not start a recommended specialty drug when newly diagnosed with leukemia. Policy changes are needed to ensure optimal access to specialty medications under Medicare Part D. Philadelphia, PA : Leonard Davis Institute of Health Economics, 2016 Leonard Davis Institute of Health Economics, issuing body. Technical Report Text Illustrations 1 online resource (1 PDF file (2 pages)) nlm:nlmuid-101680603-pdf 101680603 http://resource.nlm.nih.gov/101680603 English United States Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. https://creativecommons.org/licences/by/4.0